One-Health: a Safe, Efficient, Dual-Use Vaccine for Humans and Animals against Middle East Respiratory Syndrome Coronavirus and Rabies Virus

ABSTRACT Middle East respiratory syndrome coronavirus (MERS-CoV) emerged in 2012 and is a highly pathogenic respiratory virus. There are no treatment options against MERS-CoV for humans or animals, and there are no large-scale clinical trials for therapies against MERS-CoV. To address this need, we developed an inactivated rabies virus (RABV) that contains the MERS-CoV spike (S) protein expressed on its surface. Our initial recombinant vaccine, BNSP333-S, expresses a full-length wild-type MERS-CoV S protein; however, it showed significantly reduced viral titers compared to those of the parental RABV strain and only low-level incorporation of full-length MERS-CoV S into RABV particles. Therefore, we developed a RABV-MERS vector that contained the MERS-CoV S1 domain of the MERS-CoV S protein fused to the RABV G protein C terminus (BNSP333-S1). BNSP333-S1 grew to titers similar to those of the parental vaccine vector BNSP333, and the RABV G–MERS-CoV S1 fusion protein was efficiently expressed and incorporated into RABV particles. When we vaccinated mice, chemically inactivated BNSP333-S1 induced high-titer neutralizing antibodies. Next, we challenged both vaccinated mice and control mice with MERS-CoV after adenovirus transduction of the human dipeptidyl peptidase 4 (hDPP4) receptor and then analyzed the ability of mice to control MERS-CoV infection. Our results demonstrated that vaccinated mice were fully protected from the MERS-CoV challenge, as indicated by the significantly lower MERS-CoV titers and MERS-CoV and mRNA levels in challenged mice than those in unvaccinated controls. These data establish that an inactivated RABV-MERS S-based vaccine may be effective for use in animals and humans in areas where MERS-CoV is endemic. IMPORTANCE Rabies virus-based vectors have been proven to be efficient dual vaccines against rabies and emergent infectious diseases such as Ebola virus. Here we show that inactivated rabies virus particles containing the MERS-CoV S1 protein induce potent immune responses against MERS-CoV and RABV. This novel vaccine is easy to produce and may be useful to protect target animals, such as camels, as well as humans from deadly MERS-CoV and RABV infections. Our results indicate that this vaccine approach can prevent disease, and the RABV-based vaccine platform may be a valuable tool for timely vaccine development against emerging infectious diseases.

[1]  I. Sola,et al.  Molecular Basis of Coronavirus Virulence and Vaccine Development , 2016, Advances in Virus Research.

[2]  M. Yahia Saudi Arabia , 2016, Nature.

[3]  K. Modjarrad MERS-CoV vaccine candidates in development: The current landscape , 2016, Vaccine.

[4]  H. Feldmann,et al.  A Comparative Review of Animal Models of Middle East Respiratory Syndrome Coronavirus Infection , 2016, Veterinary pathology.

[5]  D. Swerdlow,et al.  Clinicopathologic, Immunohistochemical, and Ultrastructural Findings of a Fatal Case of Middle East Respiratory Syndrome Coronavirus Infection in the United Arab Emirates, April 2014 , 2016, The American Journal of Pathology.

[6]  S. Perlman,et al.  Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus , 2015, Cellular and Molecular Immunology.

[7]  Lloyd H. Michael,et al.  The Guide for the Care and Use of Laboratory Animals. , 2016, ILAR journal.

[8]  P. Jahrling,et al.  Preclinical Development of Inactivated Rabies Virus-Based Polyvalent Vaccine Against Rabies and Filoviruses. , 2015, The Journal of infectious diseases.

[9]  S. Yerly,et al.  The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial. , 2015, The Lancet. Infectious diseases.

[10]  S. Perlman,et al.  Identification of the Mechanisms Causing Reversion to Virulence in an Attenuated SARS-CoV for the Design of a Genetically Stable Vaccine , 2015, PLoS pathogens.

[11]  Shibo Jiang,et al.  Middle East respiratory syndrome: current status and future prospects for vaccine development , 2015, Expert opinion on biological therapy.

[12]  N. Sardesai,et al.  A synthetic consensus anti–spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates , 2015, Science Translational Medicine.

[13]  Ulas Bagci,et al.  Evaluation of candidate vaccine approaches for MERS-CoV , 2015, Nature Communications.

[14]  Y. Guan,et al.  Emerging Problems in Infectious Diseases Lessons to learn from MERS-CoV outbreak in South Korea , 2015 .

[15]  G. Yancopoulos,et al.  Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection , 2015, Proceedings of the National Academy of Sciences.

[16]  S. Yi,et al.  Epidemiological investigation of MERS-CoV spread in a single hospital in South Korea, May to June 2015. , 2015, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[17]  G. Sutter,et al.  Protective Efficacy of Recombinant Modified Vaccinia Virus Ankara Delivering Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein , 2015, Journal of Virology.

[18]  M. Frieman,et al.  Growth and Quantification of MERS‐CoV Infection , 2015, Current protocols in toxicology / editorial board, Mahin D. Maines (editor-in-chief) ... [et al.].

[19]  R. Cattaneo,et al.  Reverse genetics of Mononegavirales: How they work, new vaccines, and new cancer therapeutics. , 2015, Virology.

[20]  W. Tan,et al.  Systemic and mucosal immunity in mice elicited by a single immunization with human adenovirus type 5 or 41 vector-based vaccines carrying the spike protein of Middle East respiratory syndrome coronavirus , 2015, Immunology.

[21]  Yang Yang,et al.  The amino acids 736-761 of the MERS-CoV spike protein induce neutralizing antibodies: implications for the development of vaccines and antiviral agents. , 2014, Viral immunology.

[22]  L. Pelkmans,et al.  Coronavirus Cell Entry Occurs through the Endo-/Lysosomal Pathway in a Proteolysis-Dependent Manner , 2014, PLoS pathogens.

[23]  L. Madoff,et al.  Health-care associate transmission of Middle East Respiratory Syndrome Corona virus, MERS-CoV, in the Kingdom of Saudi Arabia , 2014, International Journal of Infectious Diseases.

[24]  H. Feldmann,et al.  Rhabdovirus-Based Vaccine Platforms against Henipaviruses , 2014, Journal of Virology.

[25]  Christian Drosten,et al.  Evidence for camel-to-human transmission of MERS coronavirus. , 2014, The New England journal of medicine.

[26]  M. Schnell,et al.  Recombinant rabies virus particles presenting botulinum neurotoxin antigens elicit a protective humoral response in vivo , 2014, Molecular therapy. Methods & clinical development.

[27]  Shibo Jiang,et al.  Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments—The importance of immunofocusing in subunit vaccine design , 2014, Vaccine.

[28]  A. Gambotto,et al.  Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB/c mice , 2014, Vaccine.

[29]  M. Frieman,et al.  Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice , 2014, Vaccine.

[30]  Z. Memish MERS-COV , 2014, International Journal of Infectious Diseases.

[31]  R. Baric,et al.  Rapid generation of a mouse model for Middle East respiratory syndrome , 2014, Proceedings of the National Academy of Sciences.

[32]  Shibo Jiang,et al.  Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines , 2014, Vaccine.

[33]  Krystal L. Matthews,et al.  Wild-type and innate immune-deficient mice are not susceptible to the Middle East respiratory syndrome coronavirus. , 2014, The Journal of general virology.

[34]  C. Wirblich,et al.  Alanine scanning of the rabies virus glycoprotein antigenic site III using recombinant rabies virus: implication for post-exposure treatment. , 2013, Vaccine.

[35]  Zhaohui Qian,et al.  Role of the Spike Glycoprotein of Human Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Virus Entry and Syncytia Formation , 2013, PloS one.

[36]  Michael G. Katze,et al.  Middle East respiratory syndrome coronavirus (MERS-CoV) causes transient lower respiratory tract infection in rhesus macaques , 2013, Proceedings of the National Academy of Sciences.

[37]  I. Sola,et al.  Engineering a Replication-Competent, Propagation-Defective Middle East Respiratory Syndrome Coronavirus as a Vaccine Candidate , 2013, mBio.

[38]  M. Katze,et al.  Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV–infected rhesus macaques , 2013, Nature Medicine.

[39]  M. Frieman,et al.  Emergence of the Middle East Respiratory Syndrome Coronavirus , 2013, PLoS pathogens.

[40]  Z. Memish,et al.  Middle East respiratory syndrome coronavirus infections in health care workers. , 2013, The New England journal of medicine.

[41]  A. Debnath,et al.  Identification of a Receptor-Binding Domain in the S Protein of the Novel Human Coronavirus Middle East Respiratory Syndrome Coronavirus as an Essential Target for Vaccine Development , 2013, Journal of Virology.

[42]  S Cauchemez,et al.  Transmission scenarios for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) and how to tell them apart. , 2013, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[43]  H. Feldmann,et al.  Antibody Quality and Protection from Lethal Ebola Virus Challenge in Nonhuman Primates Immunized with Rabies Virus Based Bivalent Vaccine , 2013, PLoS pathogens.

[44]  H. Feldmann,et al.  Pneumonia from human coronavirus in a macaque model. , 2013, The New England journal of medicine.

[45]  S. Perlman,et al.  Complete Protection against Severe Acute Respiratory Syndrome Coronavirus-Mediated Lethal Respiratory Disease in Aged Mice by Immunization with a Mouse-Adapted Virus Lacking E Protein , 2013, Journal of Virology.

[46]  Christian Drosten,et al.  Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC , 2013, Nature.

[47]  F. Cliquet,et al.  Evaluation of an ELISA to detect rabies antibodies in orally vaccinated foxes and raccoon dogs sampled in the field. , 2013, Journal of virological methods.

[48]  WHO Statement on the third meeting of the IHR Emergency committee concerning Middle East respiratory syndrome coronavirus (MERS-CoV). , 2013, Releve epidemiologique hebdomadaire.

[49]  P. Jahrling,et al.  A replication-deficient rabies virus vaccine expressing Ebola virus glycoprotein is highly attenuated for neurovirulence. , 2012, Virology.

[50]  A. Osterhaus,et al.  Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. , 2012, The New England journal of medicine.

[51]  P. Jahrling,et al.  Further characterization of the immune response in mice to inactivated and live rabies vaccines expressing Ebola virus glycoprotein. , 2012, Vaccine.

[52]  Kevin W Eliceiri,et al.  NIH Image to ImageJ: 25 years of image analysis , 2012, Nature Methods.

[53]  F. Cliquet,et al.  Evaluation of ELISA for detection of rabies antibodies in domestic carnivores. , 2012, Journal of virological methods.

[54]  P. Jahrling,et al.  Inactivated or Live-Attenuated Bivalent Vaccines That Confer Protection against Rabies and Ebola Viruses , 2011, Journal of Virology.

[55]  C. Schwegmann-Wessels,et al.  The Spike Protein of Infectious Bronchitis Virus Is Retained Intracellularly by a Tyrosine Motif , 2007, Journal of Virology.

[56]  F. Boué,et al.  A quantitative indirect ELISA to monitor the effectiveness of rabies vaccination in domestic and wild carnivores. , 2007, Journal of immunological methods.

[57]  R. Pomerantz,et al.  Rabies virus glycoprotein as a carrier for anthrax protective antigen , 2006, Virology.

[58]  G. Herrler,et al.  Intracellular Transport of the S Proteins of Coronaviruses , 2006, Advances in experimental medicine and biology.

[59]  L. Enjuanes,et al.  A Novel Sorting Signal for Intracellular Localization Is Present in the S Protein of a Porcine Coronavirus but Absent from Severe Acute Respiratory Syndrome-associated Coronavirus , 2004, Journal of Biological Chemistry.

[60]  M. Aubert,et al.  Elimination of terrestrial rabies in Western European countries. , 2004, Developments in biologicals.

[61]  R. Pomerantz,et al.  Covalently Linked Human Immunodeficiency Virus Type 1 gp120/gp41 Is Stably Anchored in Rhabdovirus Particles and Exposes Critical Neutralizing Epitopes , 2003, Journal of Virology.

[62]  J. Orenstein,et al.  Functional Human Immunodeficiency Virus Type 1 (HIV-1) Gag-Pol or HIV-1 Gag-Pol and Env Expressed from a Single Rhabdovirus-Based Vaccine Vector Genome , 2003, Journal of Virology.

[63]  R. Pomerantz,et al.  Second-Generation Rabies Virus-Based Vaccine Vectors Expressing Human Immunodeficiency Virus Type 1 Gag Have Greatly Reduced Pathogenicity but Are Highly Immunogenic , 2003, Journal of Virology.

[64]  J. Dubuisson,et al.  Live and killed rhabdovirus-based vectors as potential hepatitis C vaccines. , 2002, Virology.

[65]  R. Pomerantz,et al.  Recombinant rabies virus as potential live-viral vaccines for HIV-1. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[66]  K. Conzelmann,et al.  Molecular cloning and complete nucleotide sequence of the attenuated rabies virus SAD B19. , 1990, Virology.